![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Interleukin (IL)-11 belongs to the IL-6 family of cytokines, discovered over 30 years ago. While early studies focused on the ability of IL-11 to stimulate megakaryocytopoiesis, the importance of this cytokine to inflammatory disease and cancers is only just beginning to be uncovered. This review outlines recent advances in our understanding of IL-11 biology, and highlights the development of novel therapeutics with the potential for clinical targeting of signaling by this cytokine in multiple diseases.
Keywords:
Disclosure statement
The authors declare no conflicts of interest.
Additional information
Funding
The laboratory of TLP is supported by the Victorian State Government Operational Infrastructure support Support Program and by the National Health and Medical Research Council (NHMRC) of Australia Project Grants (1080498; 1098643; 1147621). TLP is a Victorian Cancer Agency Fellow and WEHI Dyson Bequest Centenary Fellow. This work was also supported by grants from National Health and Medical Research Foundation.